New findings highlight how the presumed meaning of medical terms may vary among patients and physicians.

No increased infections from long-term eosinophil depletion occurred.

No significant difference in home-based vs clinic-based intervention.

Currently there is no approved treatment to prevent relapses of NMOSD.

The number of AFM cases has been increasing since first reported in 2012.

An analysis of the launch price of drugs for hypertension, asthma, rheumatoid arthritis, schizophrenia and colorectal cancer.

The currently recommended schedule collectively has an excellent safety profile.

First case–control study to explore the prevalence of and risk factors for gout in patients with HIV.

Findings from a new review of the evidence, published in the Lancet.

Findings from the Defining best Management for Adults with Chronic Rhinosinusitis (MACRO) programme.

There is a substantial negative impact of multidrug-resistant Gram-negative bacteria on empirical antibiotic therapy for cancer patients—in many cases resulting in mortality. Dr Carlota Gudiol believes that considering patients’ individual risks for antibacterial resistance, and the local epidemiology of treatment centres can help guide clinical decision-making.

According to Professor Victor Nizet, the future of antibiotic treatment may not target the microbes per se, but rather the host–pathogen interface.

A non-antibiotic drug–bacteria screen identified novel interactions, suggesting that some human-targeted drugs significantly impact the gut microbiome, potentially causing side effects and antibiotic resistance. This screen is a resource of representative gut bacteria strains and growth media for further in vitro studies.

By activating the bacterial SOS response, chemotherapy treatments promote antibiotic resistance and bacterial translocation.